# **Topical Collection**

# Therapeutic Agents for Neurological Disorders

## Message from the Collection Editor

Neurological disorders are disabling conditions that encompass, but are not limited to, cerebrovascular diseases, epilepsy, dementias (Alzheimer's, frontotemporal and others), multiple sclerosis, movement disorders (Parkinson's, amvotrophic lateral sclerosis and others), brain tumors and neuroinfections. amongst other issues. Treatments for neurological disorders are challenging, but numerous advancements have been made in identifying mechanisms and delineating the pathways underlying these diseases. Advances in technologies that garner information from the fields of bioinformatics and next-generation and whole-genome sequencing have added invaluable support in identifying "culprit" genes and proteins. Using this information, scientists and clinicians have ventured into areas previously deemed "fiction". This Special Issue aims to draw together research from experts in the field that highlight therapeutic agents and strategies, helping to identify future directions that will lead to discoveries and therapies for neurological disorders.

## **Collection Editor**

Dr. Damian Holsinger

Neuroscience, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2006, Australia



## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/221332

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

#### Editor-in-Chief

#### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

### **Author Benefits**

### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

